The rise of Sildenafil initially sparked a boom for pharma, however recent shifts present a uncertain picture for shareholders. Generic alternatives are reducing earnings, and persistent patent challenges add more https://cecilywqqc866787.ssnblog.com/39823470/sildenafil-and-pharma-a-volatile-bet